Main content

    Lung: Non Small Cell Advanced, Tissue Repository Clinical Trials

    Adult Clinical Trials Main Page

    CPMC Cancer Services

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    NCI National Cancer Institute

    Contact:
    Tracy Paris
    415-600-3241 Email parist@cpmcri.org    		 Lung Cancer Specimen Repository Protocol, Ancillary. Subjects with lung cancer Active/Enrolling
    Principal Investigator:
    NCI National Cancer Institute

    Contact:
    Tracy Paris
    415-600-3241
    Email parist@cpmcri.org    		 Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Never Smokers With Stage IIIB and IV Primary Lung Adenocarcinomas. Subjects with lung cancer who have never smoked Active/Enrolling
    Principal Investigator:
    NCI National Cancer Institute

    Contact:
    Tracy Paris
    415-600-3241
    Email parist@cpmcri.org    		 Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) In Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenoBAC). Subjects with Stage IIIB and IV Bronchioloalveolar Carcinomba (BAC) and Adenocarcinma with BAC features (AdenoBAC) Active/Enrolling
    Principal Investigator:
    NCI National Cancer Institute

    Contact:
    Tracy Paris
    415-600-3241
    Email parist@cpmcri.org    		 A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer. Subjects with histologically or cytologically proven diagnosis of Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer (NSCLC) Active/Enrolling
    Principal Investigator:
    NCI National Cancer Institute

    Contact:
    Tracy Paris
    415-600-3241
    Email parist@cpmcri.org    		 A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely resected Stage IB-IIIA Non Small Cell Lung Cancer (NSCLC). Subjects who must have undergone complete resection of their Non Small Cell Lung Cancer (NSCLC) Active/Enrolling
    Principal Investigator:
    Alan Kramer, MD

    Contact:
    Anna Ruiz
    415-600-3214
    Email RuizAC@cpmcri.org    		 A Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Subjects who have stage IIIB or stage IV (metastatic) non-small cell lung cancer (NSCLC) and have received treatment with one prior platinum based chemotherapy Active/Enrolling


    updated: 9/2010

    Back to top